Conditions: Bacterial Infections
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 598
Healthy volunteers: no

Brief summary:
This study is aimed to evaluate the efficacy and safety between Tedizolid 200mg daily (intra venous) I.V. to oral for 6-day treatment compared with that of Linezolid 600mg twice daily I.V. to oral for 10-day treatment Acute Bacterial Skin and skin structure infection (ABSSSI).This is a double-blind, randomized, active control, 7-10days treatment for all subjects.

Detailed description:
Number of participants with adverse evnets as a measure of safety and tolerability will be covered in Adverse Events section.

ABSSSI Efficacy Safety Tedizolid Phosphate Linezolid

Arms:
arm 1: Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo. arm 2: Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.

Interventions: intervention 1: Tedizolid (BAY119-2631) intervention 2: Placebo Tedizolid (BAY119-2631) intervention 3: Linezolid intervention 4: Placebo Linezolid
Intervention descriptions: intervention 1: 50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days intervention 2: 50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days intervention 3: 50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days intervention 4: 50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days

Protocol document: